Nektar Therapeutics

NKTR

$71.00

Name : Nektar Therapeutics

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $1,444,252,800.00

EPSttm : -9.83

Nektar Therapeutics

$71.00

7.05%

$4.68

Float Short %

16.4

Margin Of Safety %

Put/Call OI Ratio

0.55

EPS Next Q Diff

-0.72

EPS Last/This Y

0.38

EPS This/Next Y

-3.54

Price

71.03

Target Price

123.43

Analyst Recom

Performance Q

19.81

Relative Volume

Beta

-1.01

Ticker: NKTR

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-13	NKTR	36.61	0.43	0.67	24653
2026-01-14	NKTR	36.07	0.41	1.24	24408
2026-01-15	NKTR	35.26	0.42	1.23	24475
2026-01-16	NKTR	37.67	0.39	0.19	24081
2026-01-20	NKTR	36.2	0.41	0.59	21360
2026-01-21	NKTR	36.92	0.43	0.07	21425
2026-01-22	NKTR	36.5	0.43	0.19	21513
2026-01-23	NKTR	37.13	0.43	0.03	21660
2026-01-26	NKTR	37.25	0.42	0.50	21946
2026-01-27	NKTR	38.07	0.42	0.03	22001
2026-01-28	NKTR	35.9	0.42	0.13	22052
2026-01-29	NKTR	35.17	0.42	1.69	23263
2026-01-30	NKTR	37.44	0.43	0.05	23469
2026-02-02	NKTR	38.08	0.40	0.50	24611
2026-02-03	NKTR	38.88	0.42	0.31	28282
2026-02-05	NKTR	35.14	0.41	8.57	29285
2026-02-09	NKTR	36.93	0.40	1.18	29660
2026-02-10	NKTR	55.51	0.41	0.39	30094
2026-02-11	NKTR	66.39	0.44	0.76	33298
2026-02-12	NKTR	70.95	0.55	1.34	37779
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-13	NKTR	36.67	-28.9	-	-8.32
2026-01-14	NKTR	36.06	-28.9	-	-8.32
2026-01-15	NKTR	35.33	-28.9	-	-8.32
2026-01-16	NKTR	37.58	-28.9	-	-8.32
2026-01-20	NKTR	36.26	-28.9	-	-8.32
2026-01-21	NKTR	36.89	-28.9	-	-8.32
2026-01-22	NKTR	36.53	-28.9	-	-8.32
2026-01-23	NKTR	37.13	-46.2	-	-8.32
2026-01-26	NKTR	37.26	-28.9	-	-8.32
2026-01-27	NKTR	38.01	-28.9	-	-8.32
2026-01-28	NKTR	35.98	-28.9	-	-8.32
2026-01-29	NKTR	35.18	-28.9	-	-8.32
2026-01-30	NKTR	37.33	-28.9	-	-8.32
2026-02-02	NKTR	38.06	-28.9	-	-8.32
2026-02-03	NKTR	38.85	-28.9	-	-8.32
2026-02-04	NKTR	37.60	-28.9	-	-8.32
2026-02-05	NKTR	35.14	-28.9	-	-8.32
2026-02-06	NKTR	36.77	-28.9	-	-8.32
2026-02-09	NKTR	37.03	-28.9	-	-8.32
2026-02-10	NKTR	56.04	-28.9	-	-8.32
2026-02-11	NKTR	66.43	-28.9	-	-8.32
2026-02-12	NKTR	71.03	-28.9	-	-8.32
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-13	NKTR	-8.83	41.21	14.65
2026-01-14	NKTR	-8.83	41.21	14.65
2026-01-15	NKTR	-8.83	41.21	14.65
2026-01-16	NKTR	-8.83	41.21	14.65
2026-01-20	NKTR	-8.83	40.83	14.65
2026-01-21	NKTR	-8.83	40.83	14.65
2026-01-22	NKTR	-8.83	40.83	14.65
2026-01-23	NKTR	-9.89	40.83	14.65
2026-01-26	NKTR	-9.89	39.79	14.65
2026-01-27	NKTR	-9.89	39.79	14.65
2026-01-28	NKTR	-10.01	39.79	16.29
2026-01-29	NKTR	-10.01	39.79	16.29
2026-01-30	NKTR	-10.01	39.79	16.29
2026-02-02	NKTR	-10.01	40.07	16.29
2026-02-03	NKTR	-10.01	40.07	16.29
2026-02-04	NKTR	-10.01	40.07	16.29
2026-02-05	NKTR	-10.01	40.07	16.29
2026-02-06	NKTR	-10.01	40.07	16.29
2026-02-09	NKTR	-10.01	40.80	16.29
2026-02-10	NKTR	-10.01	40.80	16.29
2026-02-11	NKTR	-10.01	40.80	16.40
2026-02-12	NKTR	-10.01	40.80	16.40
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

-1.87

Avg. EPS Est. Current Quarter

-2.9

Avg. EPS Est. Next Quarter

-2.59

Insider Transactions

-10.01

Institutional Transactions

40.8

Beta

-1.01

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

82.3

Max Drawdown 5-Year %

-98.3

Target Price

123.43

P/E

Forward P/E

PEG

P/S

23.07

P/B

16.4

P/Free Cash Flow

EPS

-7.94

Average EPS Est. Cur. Y

-8.32

EPS Next Y. (Est.)

-11.86

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-192.87

Relative Volume

Return on Equity vs Sector %

-169.8

Return on Equity vs Industry %

-153.4

EPS 1 7Days Diff

-8.3

EPS 1 30Days Diff

-8.32

EBIT Estimation

Nektar Therapeutics

Sector: Healthcare

Industry: Biotechnology

Employees: 61

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

stock quote shares NKTR – Nektar Therapeutics Stock Price stock today

news today NKTR – Nektar Therapeutics stock forecast ,stock prediction 2023 2024 2025

marketwatch NKTR – Nektar Therapeutics yahoo finance google finance

stock history NKTR – Nektar Therapeutics invest stock market

stock prices NKTR premarket after hours

ticker NKTR fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: NKTR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y